India Considers Sponsoring Rare Drugs Through First Two Trial Phases
This article was originally published in PharmAsia News
An arm of India's government proposes public funding of early-stage clinical trials if they are conducted at 11 national institutes. The Department of Pharmaceuticals proposes the National Institutes of Pharmaceutical Education and Research receive the funding to focus on developing new drugs for neglected diseases. Under the plan, the government would assist Phase I and Phase II trials to help spur a part of the drug-development process that has the most risk. After surviving the first two trial phases, NIPERS would hand the drug or treatment to private industry to develop further in Phase III trials. (Click here for more
You may also be interested in...
Teligent has followed through with plans to condense its outstanding shares to raise their value and maintain a stock-exchange listing. Meanwhile, the company revealed a sizeable loss for the first quarter of this year, as it gave the latest on its warning letter-stricken facility in Buena, New Jersey.
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.